患有ICAM1误解变异的非裔美国女性心力衰竭风险
Prarthana J Dalal1, Pedro Giro2, Laura J Rasmussen-Torvik3
1Division of Hematology and Oncology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
JACC. Heart failure
|March 26, 2024
概括
ICAM1 rs5491遗传变体增加了70岁及以上的非洲裔美国女性心力衰竭与保留射出分数 (HFpEF) 风险. 这一发现突显了HFpEF的特定年龄的遗传风险.
科学领域:
- 心血管遗传学 心血管遗传学
- 药物基因组学 药物基因组学
- 流行病学 流行病学
背景情况:
- 一种常见的ICAM1基因变异 (rs5491;p.K56M) 与非裔美国人心力衰竭 (HF) 住院治疗有关.
- 尽管如此,rs5491与心力衰竭的特定关联以及它与女性年龄的关系仍然不清楚.
研究的目的:
- 评估与ICAM1 p.K56M (rs5491) 变种相关的高风险及其亚型.
- 调查年龄是否改变了非裔美国女性rs5491和HFpEF风险之间的关联.
主要方法:
- 利用来自妇女健康倡议 (WHI) 非洲裔美国妇女队伍的数据来检查rs5491和HF亚型之间的关联.
- 评估年龄作为RS5491-HF住院关联的潜在修饰因素.
- 从WHI和动脉样硬化多民族研究 (MESA) 收集的数据进行进一步分析.
主要成果:
- 在WHI队列中,rs5491变异与整体HF风险无关.
- 年龄显著改变了rs5491和HFpEF住院之间的关联 (相互作用P=0.04).
- rs5491在70岁及以上的女性中增加了HFpEF风险 (HR1.82;P=0.002),这种效应在汇集的WHI和MESA分析中得到加强 (相互作用P=0.009).
结论:
- ICAM1 p.K56M (rs5491) 变种与70岁及以上的非洲裔美国女性高血压发作风险增加有关.
- 年龄是一个关键因素在遗传易感性HFpEF授予rs5491.1.
更多相关视频
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
3.1K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.5K
相关概念视频
01:17Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:26Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370